Historically, people with amyotrophic lateral sclerosis (ALS) experience a relentless decline in neurological function that ...

Early initiation of tofersen (Qalsody) was associated with a numerically slower decline in people with SOD1 amyotrophic ...

A new drug may slow progression of -- and even reverse -- symptoms of a rare form of amyotrophic lateral sclerosis, or ALS, a ...

The FDA is raising the bar for approval of CAR T-cell therapies in oncology. Under plans outlined by the FDA’s biologics chief Vinay Prasad, M.D., the agency will require developers of many CAR-Ts to ...

LA JOLLA, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company listed on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange ...

BOSTON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today ...

In a groundbreaking study, researchers at Tel Aviv University, leading a large-scale international team of scientists, say they have identified – and neutralized – an RNA molecule that can stop the ...

Introduction: Compelling evidence has linked liver-specific microRNA-122 (miR-122) expression with hepatic fat distribution; however, little is known about the relations between changes in circulating ...

A New York Times health reporter explains what clinical trials are, why they are important and how they can help inform us. Credit...Ricardo Tomás Supported by By Nina Agrawal Nina Agrawal is a health ...

Researchers at Tel Aviv University led a large-scale international study that opens a new avenue for treating the fatal degenerative disease ALS, considered incurable until now. The researchers ...

Oct 15 (Reuters) - Eli Lilly's (LLY.N), opens new tab experimental weight-loss pill showed superior blood sugar control in diabetic patients across two late-stage trials, the company said on Wednesday ...